Glaxo's Imitrex injectable sumatriptan
Will be reviewed for use in the treatment of migraine by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on Oct. 25. Glaxo filed the NDA (#20-080) for injectable sumatriptan on June 29, 1990 and filed for approval of a slower-acting oral form on Dec. 14, 1990. On Oct. 24, the advisory committee meeting will be closed to discuss trade secret and/or confidential information on pending INDs. Glaxo's drug will be reviewed in an open meeting scheduled for 8 a.m.-5 p.m. The committee will meet at FDA's Parklawn Bldg., Conference Rooms D&E. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth